everolimus / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 471 Diseases   207 Trials   207 Trials   10577 News 


«12...5859606162636465666768...132133»
  • ||||||||||  tamoxifen / Generic mfg., everolimus / Generic mfg.
    Review, Journal:  Therapeutic drug monitoring of oral targeted antineoplastic drugs. (Pubmed Central) -  Nov 12, 2020   
    These cells enrichment was associated with better immunotherapy response which indicated these cells potentially be crucial in immunotherapy. Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, P1 data, Journal:  A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors. (Pubmed Central) -  Nov 12, 2020   
    P1
    Sub-therapeutic concentrations and severe adverse events are current challenges in OAD treatment, which can both be addressed by the application of TDM-guided dosing, ensuring concentrations within the therapeutic window. The maximum tolerated dose of cotreatment with bevacizumab and everolimus was 8 mg/kg of bevacizumab and 4 mg/m of everolimus in a 4-week cycle for children with recurrent solid tumors.
  • ||||||||||  dexamethasone / Generic mfg., everolimus / Generic mfg.
    Enrollment closed, Enrollment change:  MIST: Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer (clinicaltrials.gov) -  Nov 12, 2020   
    P3,  N=39, Active, not recruiting, 
    The maximum tolerated dose of cotreatment with bevacizumab and everolimus was 8 mg/kg of bevacizumab and 4 mg/m of everolimus in a 4-week cycle for children with recurrent solid tumors. Suspended --> Active, not recruiting | N=279 --> 39
  • ||||||||||  everolimus / Generic mfg., sorafenib / Generic mfg.
    Enrollment closed, Trial completion date, Trial primary completion date, Metastases:  Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone (clinicaltrials.gov) -  Nov 10, 2020   
    P2,  N=35, Active, not recruiting, 
    In conclusion, our results provide moderate evidence that fulvestrant plus palbociclib and AI plus everolimus were the most effective treatments, while the efficacy and safety of fulvestrant plus palbociclib was obviously superior in some specific clinical situations. Completed --> Active, not recruiting | Trial completion date: Mar 2020 --> Mar 2021 | Trial primary completion date: Dec 2018 --> Dec 2020 | Completed --> Active, not recruiting
  • ||||||||||  Sutent (sunitinib) / Pfizer
    Enrollment open:  Mobile Application to Collect PRO Data in NET Patients (clinicaltrials.gov) -  Nov 9, 2020   
    P=N/A,  N=2000, Recruiting, 
    Similar, although not significant, results were observed in everolimus-treated cohort for PFS Conclusion As it was described previously in operated PanNET, our SPI also seems to own predictive role in patients with advanced PanNET treated with CAPTEM or everolimus. Not yet recruiting --> Recruiting
  • ||||||||||  everolimus / Generic mfg.
    Journal:  The role of optical coherence tomography guidance in scaffold versus stent optimization. (Pubmed Central) -  Nov 6, 2020   
    Compared to drug-eluting stents, Absord scaffold was associated with a significantly higher rate of optical coherence tomography-identified intraprocedural complications necessitating further modifications. The study provides some hints on the reasons of scaffolds failure in current PCI practice; it offers a new insight for the enhancement of BRS safety and presents and adds to the growing literature for successful BRS utilization.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Efficacy and Safety of a Combination of Thrombopoietin Receptor Agonist with an Immunosuppressant Therapy for the Management of Multirefractory Adult ITP: Results from a Retrospective, Multicenter, Observational Study (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3461;    
    Multirefractory ITP was defined as disease not responding to rituximab, to splenectomy (or contraindication to splenectomy), and to the 2 TPO-Ras licensed in France (romiplostim and eltrombopag) administered at the maximal approved dose...The combination regiment included eltrombopag (n=18) or romiplostim (n=13), associated with either mycophenolate mofetil (n=15), azathioprine (n=12), cyclophosphamide (n=2), ciclosporine (n=1), or everolimus (n=1)...Nineteen patients (61%) had no therapeutic intervention other than the combined treatment, while 10 patients were also given corticosteroids (either short course of high dose steroids [n=5], or on a long-term at low dose [n=5]), and/or hydroxychloroquine (n=5)...Conclusion In summary, these data show that most of the patients managed for multirefractory ITP may benefit from the combination of TPOra with an immunosuppressant therapy by achieving a durable response. The safety profile of this combination in this population seems acceptable.
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] Pure Red Cell Aplasia in Systemic Lupus Erythematosus, a Nationwide Retrospective Cohort and Review of the Literature (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_3387;    
    Our results showed that it is a severe condition associated with high morbidity such as iron overload secondary to multiple transfusions and infections related to corticosteroids and other immunosuppressive agents. Corticosteroids were mainly not effective in monotherapy but most patients eventually achieved a response with other immunosuppressive agents.
  • ||||||||||  Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Clinical, Clinical guideline, Journal:  SEOM clinical guideline for treatment of kidney cancer (2019). (Pubmed Central) -  Nov 2, 2020   
    In patients progressing to one or two antiangiogenic tyrosine-kinase inhibitors, both nivolumab and cabozantinib in monotherapy have shown benefit in overall survival compared to everolimus. Although no clear sequence can be recommended, medical oncologists and patients should be aware of the recent advances and new strategies that improve survival and quality of life in patients with metastatic RCC.
  • ||||||||||  sirolimus / Generic mfg.
    Trial completion date, Trial primary completion date:  MIDAS: Safety and Durability of Sirolimus for Treatment of LAM (clinicaltrials.gov) -  Oct 30, 2020   
    P=N/A,  N=600, Active, not recruiting, 
    Trial primary completion date: Oct 2018 --> Feb 2020 Trial completion date: Apr 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Aug 2021
  • ||||||||||  everolimus / Generic mfg.
    Trial completion date, Trial primary completion date, Metastases:  Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium (clinicaltrials.gov) -  Oct 29, 2020   
    P2,  N=46, Active, not recruiting, 
    Trial completion date: Apr 2020 --> Aug 2021 | Trial primary completion date: Apr 2020 --> Aug 2021 Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Dec 2021
  • ||||||||||  everolimus / Generic mfg.
    Journal:  Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. (Pubmed Central) -  Oct 28, 2020   
    In particular, miR-375 expression was up-regulated by VitD in EveR cells, in which miR-375 was down-regulated compared to parental cells, with consequent inhibition of oncogenes involved in drug resistance and epithelial-mesenchymal transition (EMT) such as MTDH, YAP-1 and c-MYC. In conclusion, the results of the current study demonstrated that VitD can re-sensitize HCC cells resistant to EVE treatment triggering miR-375 up-regulation and consequently down-regulating several oncogenes responsible of EMT and drug resistance.
  • ||||||||||  everolimus / Generic mfg., sirolimus / Generic mfg.
    Journal:  Statins activate the NLRP3 inflammasome and impair insulin signalling via p38 and mTOR. (Pubmed Central) -  Oct 28, 2020   
    Rapamycin (20 nM) or the rapalog, Everolimus (20 nM) prevented atorvastatin-induced lowering of insulin-mediated phosphorylation of Akt in mouse adipose tissue. These results position p38 and mTOR as mediators of statin-induced insulin resistance in adipose tissue and highlight rapalogs as candidates to mitigate the insulin resistance and glycemic side effects of statins.
  • ||||||||||  Cotellic (cobimetinib) / Exelixis, Roche, Tecentriq (atezolizumab) / Roche
    Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases:  MEGALiT: A MolEcularly Guided Anti-Cancer Drug Off-Label Trial (clinicaltrials.gov) -  Oct 28, 2020   
    P2,  N=154, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2019 --> Apr 2020 | Trial primary completion date: Sep 2019 --> Apr 2020 Not yet recruiting --> Recruiting